Kim Schrier Stock Portfolio: 5 Stocks To Consider

3. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 74

Bristol-Myers Squibb Company (NYSE:BMY) markets biopharma products. A growing number of hedge funds have turned bullish on the stock in recent months. At the end of the third quarter of 2021, 74 hedge funds in the database of Insider Monkey held stakes worth $4.7 billion in Bristol-Myers Squibb Company (NYSE:BMY), up from 73 in the preceding quarter worth $5.2 billion. 

On October 28, per latest filings, Schrier sold Bristol-Myers Squibb Company (NYSE:BMY) stock worth around $1,000 to $15,000. The transaction in this regard was disclosed the day after it was made. 

In its Q4 2020 investor letter, Wedgewood Partners, an asset management firm, highlighted a few stocks and Bristol-Myers Squibb Company (NYSE:BMY) was one of them. Here is what the fund said:

“Bristol-Myers Squibb recently reported accelerating sales as much of the medical services industry returned to work. The Company continues to expect double-digit earnings growth over the next few years, driven by existing drugs, in addition to a broad pipeline of new drugs and indications. While the market remains fixated on a couple of patent expirations that could occur over the next several years, we think this is well-known at this point, yet the market still undervalues a couple of key acquisitions the Company has made in the past few years, particularly Celgene, which was acquired for a song.”